Indaptus Therapeutics Q3 net loss narrows 65% to $1.05 million
INDP•Indaptus Therapeutics’ third-quarter 2026 net loss narrowed 65% year over year to $1.05 million. Cash, cash equivalents and short-term investments totaled about $30.6 million at September 30, and a roughly $24 million private placement closed October 16.
1. Quarterly results
Indaptus Therapeutics’ third-quarter 2026 net loss narrowed 65% year over year to $1.05 million. Research and development expenses fell 82% to $271,204, primarily due to lower Decoy20 clinical costs and reduced payroll expenses.
2. Cash and research plans
Cash, cash equivalents and short-term investments totaled approximately $30.6 million at September 30, 2026. A roughly $24 million private placement closed October 16, with approximately $3.5 million in remaining proceeds received in October. Planned research includes early-stage and preclinical evaluation of a potential neurotechnology- and neural-network-based device for certain sleep-related conditions.
